

REMARKS


The first page of the specification has been amended to insert the priority claim.

Claims 1-4, 6, and 9-17 are pending in this application. Claims 2, 3, 6, 9, and 10 have been amended and new claims 11, 13-15, and 17 have been added to remove multiple dependencies and to conform the claims to US practice. Claims 12 and 16 have been added directed to methods of controlling infections caused by cytomegalovirus. No new matter has been added.

The Commissioner is authorized to charge any fees required as a result of this Preliminary Amendment to Deposit Account 13-3372. A duplicate of this sheet is enclosed.

If the Examiner believes that a conversation with Applicants' attorney would be helpful in expediting prosecution of this application, the Examiner is invited to call the undersigned attorney.

Respectfully submitted,

A handwritten signature in black ink, reading "Barbara A. Shimei". The signature is written in a cursive style with a large, stylized 'B' and 'S'.

Barbara A. Shimei
Reg. No. 29,862
Attorney for Applicants
Bayer Pharmaceuticals Corporation
400 Morgan Lane
West Haven, CT 06516
Phone: (203) 812-2786
Fax: (203) 812-6459